Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamara Berno

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Haematology|May 25, 2012
Low-risk identification in multiple myeloma using a new 14-gene modelTiehua Chen, Tamara Berno, Maurizio Zangari
Seminars in Thrombosis and Hemostasis|October 30, 2012
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugsMaurizio Zangari, Tamara Berno, Fenghuang Zhan, et al.
Journal of Clinical Medicine|October 28, 2023
Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A ReviewAngela Napolitano, Laura De Michieli, Giulio Sinigiani, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 4, 2011
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controlsMaurizio Zangari, Tamara Berno, Fenghuang Zhan, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 7, 2021
Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center ExperienceMarcello Riva, Tamara Berno, Alberto Cipriani, et al.
European Journal of Haematology|May 1, 2012
Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myelomaGiampaolo Talamo, Kevin L Rakszawski, Witold B Rybka, et al.
Journal of the Peripheral Nervous System : JPNS|March 26, 2013
Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective studyChiara Briani, Chiara Dalla Torre, Marta Campagnolo, et al.
Bone|January 7, 2014
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitorsMaurizio Zangari, Tamara Berno, Ye Yang, et al.
Journal of the Peripheral Nervous System : JPNS|March 2, 2023
Peripheral neuropathy as clinical onset of monoclonal IgM/k-related amyloidosisChiara Briani, Sergio Ferrari, Tamara Berno, et al.
Blood|August 11, 2005
Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL)Renato Zambello, Tamara Berno, Giovanna Cannas, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Haematology|May 25, 2012
Low-risk identification in multiple myeloma using a new 14-gene modelTiehua Chen, Tamara Berno, Maurizio Zangari
Seminars in Thrombosis and Hemostasis|October 30, 2012
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugsMaurizio Zangari, Tamara Berno, Fenghuang Zhan, et al.
Journal of Clinical Medicine|October 28, 2023
Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A ReviewAngela Napolitano, Laura De Michieli, Giulio Sinigiani, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 4, 2011
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controlsMaurizio Zangari, Tamara Berno, Fenghuang Zhan, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 7, 2021
Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center ExperienceMarcello Riva, Tamara Berno, Alberto Cipriani, et al.
European Journal of Haematology|May 1, 2012
Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myelomaGiampaolo Talamo, Kevin L Rakszawski, Witold B Rybka, et al.
Journal of the Peripheral Nervous System : JPNS|March 26, 2013
Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective studyChiara Briani, Chiara Dalla Torre, Marta Campagnolo, et al.
Bone|January 7, 2014
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitorsMaurizio Zangari, Tamara Berno, Ye Yang, et al.
Journal of the Peripheral Nervous System : JPNS|March 2, 2023
Peripheral neuropathy as clinical onset of monoclonal IgM/k-related amyloidosisChiara Briani, Sergio Ferrari, Tamara Berno, et al.
Blood|August 11, 2005
Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL)Renato Zambello, Tamara Berno, Giovanna Cannas, et al.
Pageof 3